CKD Diagnosis via Plasma Protein Post-Translational Modification Analysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for diagnosing chronic kidney disease (CKD) are limited in detecting early stages and rely on physiological parameters that only indicate renal failure after it has occurred, failing to provide accurate early detection or monitoring of renal impairment before significant kidney damage.

Innovation Solution

The method involves analyzing and quantifying post-translational modifications of plasma proteins, specifically comparing patterns in patient samples to those of healthy individuals to detect specific modifications that indicate early stages of CKD, using techniques like MALDI-TOF-TOF MS/MS and immunological methods for accurate diagnosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current diagnostic methods (creatinine measurement, GFR calculation) are used, then renal failure can be detected, but only after significant kidney damage has already occurred

Engineering Contradiction:
Improveaccuracy of CKD stage diagnosisVSAvoiddelay in early detection
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

Instead of measuring physiological parameters that indicate kidney failure after it occurs (creatinine, GFR), the invention inverts the approach by measuring post-translational modifications of plasma proteins that occur before kidney damage. This reverse approach enables detection of early-stage CKD by looking for molecular changes (oxidation, carbamylation, glycosylation) that precede functional impairment, thereby resolving the contradiction between reliable diagnosis and early detection timing

Inventive Principle:
Principle #13The other way round (Inversion)

2Measurement precision

If physiological parameters (creatinine, GFR) are measured, then renal function can be assessed, but the methods are limited to detecting renal failure that has already occurred

Engineering Contradiction:
Improveability to detect early stage CKDVSAvoidapplicability to different CKD stages
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The invention makes the diagnostic approach universally applicable across all CKD stages by using post-translational modification markers that are present from early stages through end-stage renal disease. Unlike creatinine-based methods that only work after damage occurs, the PTM markers (oxidized proteins, carbamylated proteins, glycated proteins) provide a universal diagnostic tool that adapts to detect kidney impairment at any stage, resolving the contradiction between measurement precision for early detection and versatility across disease stages

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Reliability

If multiple diagnostic methods (MDRD formula, Cockroft-Gault formula, cystatin C) are used, then GFR can be calculated, but the methods yield different results and cannot accurately attribute CKD stages

Engineering Contradiction:
Improveaccuracy of CKD stage attributionVSAvoidnumber of diagnostic methods required
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention extracts the essential diagnostic information by focusing on specific post-translational modification markers (oxidation, carbamylation, glycosylation) of plasma proteins. Instead of using multiple complex formulas (MDRD, Cockroft-Gault, cystatin C) that yield conflicting results, the method extracts a simplified yet highly accurate diagnostic signal from protein modifications. This extraction approach resolves the contradiction by providing reliable CKD stage attribution through a single, unified method rather than multiple conflicting methods

Inventive Principle:
Principle #2Taking out (Extraction)

4Loss of time

If post-translational modifications of plasma proteins are analyzed, then early stage CKD can be detected, but the analysis method is more complex than standard creatinine measurement

Engineering Contradiction:
Improvetime to early diagnosisVSAvoidcomplexity of analysis method
Core Design Contradiction:
Loss of timeVSDevice complexity

Solution Approach 1:

The invention replaces the simple mechanical/chemical measurement of creatinine concentration with a more sophisticated but information-rich analysis of post-translational modifications. Instead of measuring a single metabolite (creatinine), the method uses immunological assays or mass spectrometry to detect modified proteins. This substitution resolves the contradiction by trading increased analytical complexity for dramatically improved early detection capability, enabling diagnosis before kidney damage occurs

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for reliable early diagnosis and monitoring of CKD before significant kidney damage occurs, providing a molecular-level diagnosis based on a single measurement and overcoming limitations of existing methods by identifying specific post-translational modifications that are indicative of renal impairment.

Implementation Method 1

using techniques like MALDI-TOF-TOF MS/MS

Methodology Applied
Scientific EffectMatrix-assisted laser desorption/ionization time of flight mass spectrometry:

Implementation Method 2

using techniques like MALDI-TOF-TOF MS/MS and immunological methods

Methodology Applied
Scientific EffectAntibody-antigen binding:

Data Source

PatentEP3132269B1Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins
Publication Date: 2019.12.25 EXCORLAB GMBH
  • EP3132269B1 patent drawingFigure 1A~1E
  • EP3132269B1 patent drawingFigure 2A~2F
  • EP3132269B1 patent drawingFigure 3A~3C

AI summary

The present invention relates to methods for diagnosing and/or monitoring the onset or progression of chronic kidney disease (CKD) in a patient by the analysis of post-translational modification of plasma proteins. The present invention provides improved means for diagnosing chronic kidney disease (CKD) especially for the early recognition of CKD.